High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm
Aronsson, Linus LU ; Andersson, Roland LU ; Bauden, Monika LU
; Andersson, Bodil
LU
; Bygott, Thomas
and Ansari, Daniel
LU
(2018)
In Scandinavian Journal of Gastroenterology
53(12).
p.1597-1603
- Abstract
Objective: Glycoproteomics is an emerging subfield of proteomics. Tumor-specific variations in protein glycosylation might be potential targets for the development of new cancer diagnostics. Here, we performed high-throughput screening and targeted verification of glycome alterations in serum samples from patients with pancreatic cancer and the precancerous lesion intraductal papillary mucinous neoplasm (IPMN). Material and methods: The glycosylation profile of 1000 proteins was mapped in a discovery cohort comprising serum samples from 16 individuals, including 8 patients with pancreatic cancer and 8 healthy controls. The top 10 glycoprotein biomarker candidates with the highest signal intensity difference in glycosylation levels were... (More)
Objective: Glycoproteomics is an emerging subfield of proteomics. Tumor-specific variations in protein glycosylation might be potential targets for the development of new cancer diagnostics. Here, we performed high-throughput screening and targeted verification of glycome alterations in serum samples from patients with pancreatic cancer and the precancerous lesion intraductal papillary mucinous neoplasm (IPMN). Material and methods: The glycosylation profile of 1000 proteins was mapped in a discovery cohort comprising serum samples from 16 individuals, including 8 patients with pancreatic cancer and 8 healthy controls. The top 10 glycoprotein biomarker candidates with the highest signal intensity difference in glycosylation levels were evaluated in a cohort consisting of 109 serum samples, including 49 patients with resectable pancreatic cancer, 13 patients with resectable noninvasive IPMN and 47 healthy controls, using a targeted assay. Results: Multivariable analysis defined sets of panels comprising CA19-9 and distinctively glycosylated proteins for discrimination between pancreatic cancer, IPMN and healthy controls. A panel including CA 19-9, IL.17E, B7.1 and DR6 gave an AUC of 0.988 at 100% sensitivity at 90% specificity for the discrimination of stage 1 pancreatic cancer and healthy controls. B7.1 was found to be a valuable biomarker for differentiating between IPMN and healthy controls, with better performance alone than CA 19-9. Conclusions: Measurement of protein glycosylation profiles in serum may aid in the early detection of pancreatic cancer and precursor lesions.
(Less)
- author
- Aronsson, Linus
LU
; Andersson, Roland
LU
; Bauden, Monika
LU
; Andersson, Bodil
LU
; Bygott, Thomas
and Ansari, Daniel
LU
- organization
- publishing date
- 2018-12-03
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- biomarker, early diagnosis, Glycoproteomics, intraductal papillary mucinous neoplasm, pancreatic cancer, serum
- in
- Scandinavian Journal of Gastroenterology
- volume
- 53
- issue
- 12
- pages
- 1597 - 1603
- publisher
- Taylor & Francis
- external identifiers
-
- scopus:85058126681
- pmid:30509115
- ISSN
- 0036-5521
- DOI
- 10.1080/00365521.2018.1532020
- language
- English
- LU publication?
- yes
- id
- 5114864b-b116-4286-a0c4-d7d2d68c8fdc
- date added to LUP
- 2019-01-02 09:53:05
- date last changed
- 2025-10-14 12:22:17
@article{5114864b-b116-4286-a0c4-d7d2d68c8fdc,
abstract = {{<p>Objective: Glycoproteomics is an emerging subfield of proteomics. Tumor-specific variations in protein glycosylation might be potential targets for the development of new cancer diagnostics. Here, we performed high-throughput screening and targeted verification of glycome alterations in serum samples from patients with pancreatic cancer and the precancerous lesion intraductal papillary mucinous neoplasm (IPMN). Material and methods: The glycosylation profile of 1000 proteins was mapped in a discovery cohort comprising serum samples from 16 individuals, including 8 patients with pancreatic cancer and 8 healthy controls. The top 10 glycoprotein biomarker candidates with the highest signal intensity difference in glycosylation levels were evaluated in a cohort consisting of 109 serum samples, including 49 patients with resectable pancreatic cancer, 13 patients with resectable noninvasive IPMN and 47 healthy controls, using a targeted assay. Results: Multivariable analysis defined sets of panels comprising CA19-9 and distinctively glycosylated proteins for discrimination between pancreatic cancer, IPMN and healthy controls. A panel including CA 19-9, IL.17E, B7.1 and DR6 gave an AUC of 0.988 at 100% sensitivity at 90% specificity for the discrimination of stage 1 pancreatic cancer and healthy controls. B7.1 was found to be a valuable biomarker for differentiating between IPMN and healthy controls, with better performance alone than CA 19-9. Conclusions: Measurement of protein glycosylation profiles in serum may aid in the early detection of pancreatic cancer and precursor lesions.</p>}},
author = {{Aronsson, Linus and Andersson, Roland and Bauden, Monika and Andersson, Bodil and Bygott, Thomas and Ansari, Daniel}},
issn = {{0036-5521}},
keywords = {{biomarker; early diagnosis; Glycoproteomics; intraductal papillary mucinous neoplasm; pancreatic cancer; serum}},
language = {{eng}},
month = {{12}},
number = {{12}},
pages = {{1597--1603}},
publisher = {{Taylor & Francis}},
series = {{Scandinavian Journal of Gastroenterology}},
title = {{High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm}},
url = {{http://dx.doi.org/10.1080/00365521.2018.1532020}},
doi = {{10.1080/00365521.2018.1532020}},
volume = {{53}},
year = {{2018}},
}